Assembly Biosciences (ASMB +2.7%) initiates an 80-subject proof-of-concept Phase 2 clinical trial evaluating ABI-H2158, combined with entecavir, in treatment-naïve patients with HBeAg-positive chronic hepatitis B infection without cirrhosis.
The primary endpoints are safety and the change from baseline in mean log10 HBV DNA at week 24 (efficacy measure).
The estimated primary completion date is January 2023.
Positive data from a Phase 1 trial were presented at The Liver Meeting in Boston in October 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.